Yuanlai Zou - BrightGene Bio Financial Director
| 688166 Stock | 29.55 0.68 2.36% |
Director
Yuanlai Zou is Financial Director of BrightGene Bio Medical
| Age | 54 |
| Address | Building C25-28, Suzhou, China, 215123 |
| Phone | 86 512 6262 0988 |
| Web | https://www.bright-gene.com |
BrightGene Bio Management Efficiency
The company has return on total asset (ROA) of 0.0227 % which means that it generated a profit of $0.0227 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.06 %, meaning that it generated $0.06 on every $100 dollars invested by stockholders. BrightGene Bio's management efficiency ratios could be used to measure how well BrightGene Bio manages its routine affairs as well as how well it operates its assets and liabilities. At present, BrightGene Bio's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 3.9 B, whereas Net Tangible Assets are forecasted to decline to about 1.2 B.Similar Executives
| Found 10 records | DIRECTOR Age | ||
| Pizheng Li | China Mobile Limited | 59 | |
| Cicheng Wang | JCHX Mining Management | 59 | |
| Wentao CPA | Beijing Bewinner Communications | 47 | |
| Xinyu Wang | JCHX Mining Management | 53 | |
| Wei Peng | Queclink Wireless Solutions | 45 | |
| Ning Liu | Beijing Bewinner Communications | 58 | |
| Gao Xiaoguang | Beijing Bewinner Communications | N/A | |
| Youcheng Wang | JCHX Mining Management | 56 | |
| Ronghua Li | China Mobile Limited | 59 | |
| Zhuhong Meng | JCHX Mining Management | 46 | |
Management Performance
| Return On Equity | 0.06 | ||||
| Return On Asset | 0.0227 |
BrightGene Bio Medical Leadership Team
Elected by the shareholders, the BrightGene Bio's board of directors comprises two types of representatives: BrightGene Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BrightGene. The board's role is to monitor BrightGene Bio's management team and ensure that shareholders' interests are well served. BrightGene Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BrightGene Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fang Liu, Accounting Supervisor | ||
| Nan Ding, Board Secretary | ||
| Jiandong Yuan, Chairman GM | ||
| Kai Li, Deputy Manager | ||
| Zhengye Wang, Deputy Manager | ||
| Yuanlai Zou, Financial Director |
BrightGene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BrightGene Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.06 | ||||
| Return On Asset | 0.0227 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 13.85 B | ||||
| Shares Outstanding | 422.47 M | ||||
| Shares Owned By Insiders | 39.34 % | ||||
| Shares Owned By Institutions | 18.13 % | ||||
| Price To Book | 5.18 X | ||||
| Price To Sales | 10.04 X |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in BrightGene Stock
BrightGene Bio financial ratios help investors to determine whether BrightGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BrightGene with respect to the benefits of owning BrightGene Bio security.